메뉴 건너뛰기




Volumn 11, Issue 6, 2011, Pages 729-737

The impact of reference-pricing systems in Europe: A literature review and case studies

Author keywords

drug expenditure; drug prices; drug use; generic; health outcome; pharmaceuticals; PPI; reference pricing; reimbursement; statins

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESCITALOPRAM; ESOMEPRAZOLE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LISINOPRIL; NIMESULIDE; NITRATE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TICLOPIDINE; VENLAFAXINE;

EID: 81755171232     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.70     Document Type: Review
Times cited : (41)

References (37)
  • 1
    • 0036060499 scopus 로고    scopus 로고
    • Reference-based pricing schemes: Effect on pharmaceutical expenditure resource utilization and health outcomes
    • Ioannides-Demos L, Ibrahim J, McNeil J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics 20(9), 577-591 (2002).
    • (2002) Pharmacoeconomics , vol.20 , Issue.9 , pp. 577-591
    • Ioannides-Demos, L.1    Ibrahim, J.2    McNeil, J.3
  • 3
    • 78650187179 scopus 로고    scopus 로고
    • Effects of reference pricing in pharmaceutical markets: A review
    • Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29(1), 17-33 (2011).
    • (2011) Pharmacoeconomics , vol.29 , Issue.1 , pp. 17-33
    • Galizzi, M.M.1    Ghislandi, S.2    Miraldo, M.3
  • 4
    • 33847333167 scopus 로고    scopus 로고
    • Reference drug programs: Effectiveness and policy implications
    • Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81, 17-28 (2007).
    • (2007) Health Policy , vol.81 , pp. 17-28
    • Schneeweiss, S.1
  • 5
    • 81755180922 scopus 로고    scopus 로고
    • European generic medicines association
    • Brussels Belgium
    • European Generic Medicines Association. 2008 Market Review. Brussels, Belgium (2008).
    • (2008) 2008 Market Review
  • 7
    • 77950450640 scopus 로고    scopus 로고
    • IMS Health IMS Health London UK
    • IMS Health. MIDAS Database. IMS Health, London, UK (2008).
    • (2008) MIDAS Database
  • 8
    • 77954886499 scopus 로고    scopus 로고
    • The impact of reference pricing on the switching behaviour and healthcare utilization: The case of statins in Germany
    • Stargardt T. The impact of reference pricing on the switching behaviour and healthcare utilization: the case of statins in Germany. Eur. J. Health Econ. 11, 267-277 (2010).
    • (2010) Eur. J. Health Econ. , vol.11 , pp. 267-277
    • Stargardt, T.1
  • 9
    • 26444591589 scopus 로고    scopus 로고
    • Pharmaceutical policy regarding generic drugs in Belgium
    • Simoens S, De Bruyn K, Bogaert M, Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23(8), 755-766 (2005).
    • (2005) Pharmacoeconomics , vol.23 , Issue.8 , pp. 755-766
    • Simoens, S.1    De Bruyn, K.2    Bogaert, M.3    Laekeman, G.4
  • 10
    • 33646571919 scopus 로고    scopus 로고
    • Switch patterns before and after patent expiry of omeprazole: A case study in the Netherlands
    • Klok RM, Boersma C, Oosterhuis I et al. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment. Pharmacol. Ther. 23, 1595-1600 (2006).
    • (2006) Aliment. Pharmacol. Ther. , vol.23 , pp. 1595-1600
    • Klok, R.M.1    Boersma, C.2    Oosterhuis, I.3
  • 11
    • 81755181778 scopus 로고    scopus 로고
    • College voor zorgverzekeringen
    • CVZ Diemen The Netherlands
    • College voor zorgverzekeringen. GIP Database. CVZ, Diemen, The Netherlands (2011).
    • (2011) GIP Database
  • 12
    • 33644852185 scopus 로고    scopus 로고
    • Patent drugs in Italy a short-sighted view
    • Garattini L , Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur. J. Health Econ. 7, 79-83 (2006).
    • (2006) Eur. J. Health Econ. , vol.7 , pp. 79-83
    • Garattini, L.1    Ghislandi, S.2
  • 13
    • 34848861325 scopus 로고    scopus 로고
    • The impact of generic reference pricing interventions in the statin market
    • Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy 84, 14-29 (2007).
    • (2007) Health Policy , vol.84 , pp. 14-29
    • Puig-Junoy, J.1
  • 15
    • 0042532267 scopus 로고    scopus 로고
    • The drug budget silo mentality: The DUTCH case
    • Koopmanshap M , Rutten F. The drug budget silo mentality: the Dutch case. Value Health 6(1), 46-51 (2003).
    • (2003) Value Health , vol.6 , Issue.1 , pp. 46-51
    • Koopmanshap, M.1    Rutten, F.2
  • 16
    • 14844316301 scopus 로고    scopus 로고
    • Pharmaceutical policy in Italy: Towards a structural change
    • Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 72, 53-63 (2005).
    • (2005) Health Policy , vol.72 , pp. 53-63
    • Ghislandi, S.1    Krulichova, I.2    Garattini, L.3
  • 17
    • 61849162196 scopus 로고    scopus 로고
    • Regulation and pricing of pharmaceuticals: Reference pricing of price cap regulation
    • Brekke K, Grasdal A, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing of price cap regulation? Eur. Econ. Rev. 53, 170-185 (2009).
    • (2009) Eur. Econ. Rev. , vol.53 , pp. 170-185
    • Brekke, K.1    Grasdal, A.2    Holmås, T.H.3
  • 18
    • 0036762637 scopus 로고    scopus 로고
    • Do pharmaceutical prices respond to potential patient out-of-pockets expenses
    • Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pockets expenses? Rand J. Econ. 33(3), 469-487 (2002).
    • (2002) Rand J. Econ. , vol.33 , Issue.3 , pp. 469-487
    • Pavcnik, N.1
  • 19
    • 67149137843 scopus 로고    scopus 로고
    • Effects of the German reference drug program on ex-factory prices of prescription drugs: A panel data approach
    • Augurzky B, Göhlmann S, Gress S, Wasem J. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Health Econ. 18, 421-436 (2009).
    • (2009) Health Econ. , vol.18 , pp. 421-436
    • Augurzky, B.1    Göhlmann, S.2    Gress, S.3    Wasem, J.4
  • 20
    • 0031838934 scopus 로고    scopus 로고
    • The German experience in reference pricing
    • Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 44, 73-85 (1998).
    • (1998) Health Policy , vol.44 , pp. 73-85
    • Giuliani, G.1    Selke, G.2    Garattini, L.3
  • 21
    • 33846246421 scopus 로고    scopus 로고
    • Does therapeutic reference pricing always result in cost-containment the hungarian evidence
    • Kaló Z, Muszbek N, Bodrogi J, Bidló J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80, 402-412 (2007).
    • (2007) Health Policy , vol.80 , pp. 402-412
    • Kaló, Z.1    Muszbek, N.2    Bodrogi, J.3    Bidló, J.4
  • 22
    • 45449095988 scopus 로고    scopus 로고
    • Competition in off- patent drug markets: Issues regulation and evidence
    • Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econom. Policy 23(55), 499-544 (2008).
    • (2008) Econom. Policy , vol.23 , Issue.55 , pp. 499-544
    • Kanavos, P.1    Costa-Font, J.2    Seeley, E.3
  • 23
    • 33749529098 scopus 로고    scopus 로고
    • Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditure interrupted time series analysis of cost volume and cost per volume trends in Sweden 1986-2002
    • Andersson K, Petzold M, Sonesson C, Lönnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditure? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 79, 231-243 (2006).
    • (2006) Health Policy , vol.79 , pp. 231-243
    • Andersson, K.1    Petzold, M.2    Sonesson, C.3    Lönnroth, K.4    Carlsten, A.5
  • 24
    • 15244359182 scopus 로고    scopus 로고
    • Reference pricing of pharmaceuticals for medicare: Evidence from germany the netherlands and new zealand
    • Cambridge MA, USA
    • Danzon P, Ketcham J. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. National Bureau of Economic Research, Cambridge, MA, USA (2004).
    • (2004) National Bureau of Economic Research
    • Danzon, P.1    Ketcham, J.2
  • 25
    • 78249285572 scopus 로고    scopus 로고
    • Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing
    • Puig-Junoy J , Moreno-Torres I. Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing? Health Policy 98, 186-194 (2010).
    • (2010) Health Policy , vol.98 , pp. 186-194
    • Puig-Junoy, J.1    Moreno-Torres, I.2
  • 26
    • 0034680689 scopus 로고    scopus 로고
    • Review of the literature on reference pricing
    • López-Casasnovas G , Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54, 87-123 (2000).
    • (2000) Health Policy , vol.54 , pp. 87-123
    • López-Casasnovas, G.1    Puig-Junoy, J.2
  • 27
    • 63749087204 scopus 로고    scopus 로고
    • Price control as a strategy for pharmaceutical cost containment - What has been achieved in Norway in the period 1994-2004
    • Håkonsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? Health Policy 90, 277-285 (2009).
    • (2009) Health Policy , vol.90 , pp. 277-285
    • Håkonsen, H.1    Horn, A.M.2    Toverud, E.-L.3
  • 28
    • 33846865332 scopus 로고    scopus 로고
    • Reference prices and generic medicines: what can we expect
    • Mestre-Ferrandiz J. Reference prices and generic medicines: what can we expect? J. Gen. Med. 1(1), 31-38 (2003).
    • (2003) J. Gen. Med. , vol.1 , Issue.1 , pp. 31-38
    • Mestre-Ferrandiz, J.1
  • 32
    • 0141483571 scopus 로고    scopus 로고
    • Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
    • Schneeweiss S, Soumerai S, Maclure M, Dormuth C, Walker A, Glynn R. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther. 74(4), 388-400 (2003).
    • (2003) Clin. Pharmacol. Ther. , vol.74 , Issue.4 , pp. 388-400
    • Schneeweiss, S.1    Soumerai, S.2    Maclure, M.3    Dormuth, C.4    Walker, A.5    Glynn, R.6
  • 33
    • 77950435775 scopus 로고    scopus 로고
    • Generic medicine pricing policies in Europe: Current status and impact
    • Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals 3, 471-481 (2010).
    • (2010) Pharmaceuticals , vol.3 , pp. 471-481
    • Dylst, P.1    Simoens, S.2
  • 34
    • 33746536484 scopus 로고    scopus 로고
    • Charles River Associates. European Commission Brussels Belgium
    • Charles River Associates. Innovation in the Pharmaceutical Sector. European Commission, Brussels, Belgium (2004).
    • (2004) Innovation in the Pharmaceutical Sector.
  • 35
    • 81755189128 scopus 로고    scopus 로고
    • A call to make valuable innovative medicines available in the european union background report for the ministerial conference 'Innovation and solidarity on pharmaceuticals
    • Brussels Belgium
    • Annemans L, Arickx F, Belle O et al. A call to make valuable innovative medicines available in the European Union. Background report for the ministerial conference 'Innovation and solidarity on pharmaceuticals'. RIZIV/INAMI, Brussels, Belgium (2010).
    • (2010) RIZIV/INAMI
    • Annemans, L.1    Arickx, F.2    Belle, O.3
  • 36


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.